Generation Bio Co. (NASDAQ:GBIO) Receives Consensus Rating of “Hold” from Analysts

Shares of Generation Bio Co. (NASDAQ:GBIO) have been assigned an average recommendation of “Hold” from the seven research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $8.8750.

Several analysts have recently commented on GBIO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd. Wedbush set a $5.50 price objective on shares of Generation Bio and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Zacks Research raised shares of Generation Bio to a “hold” rating in a research note on Monday, January 26th. Citigroup reiterated a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Finally, Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Generation Bio in a research note on Friday, November 7th.

Institutional Investors Weigh In On Generation Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. Deltec Asset Management LLC bought a new position in Generation Bio in the fourth quarter valued at about $185,000. Cantor Fitzgerald L. P. acquired a new position in Generation Bio during the 3rd quarter valued at about $606,000. ADAR1 Capital Management LLC bought a new position in shares of Generation Bio in the 3rd quarter valued at about $136,000. Shay Capital LLC bought a new position in shares of Generation Bio in the 3rd quarter valued at about $64,000. Finally, Militia Capital Partners LP acquired a new stake in shares of Generation Bio during the 2nd quarter worth approximately $174,000. Institutional investors own 95.22% of the company’s stock.

Generation Bio Price Performance

Shares of GBIO opened at $5.34 on Wednesday. The company has a market capitalization of $35.98 million, a P/E ratio of -0.57 and a beta of 2.05. Generation Bio has a one year low of $3.00 and a one year high of $8.20. The business’s 50 day simple moving average is $5.51 and its 200-day simple moving average is $5.61.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.